Fluoroquinolones

Correct Answer

B — Ciprofloxacin

Rationale

Ciprofloxacin is a fluoroquinolone antibiotic. Azithromycin is a macrolide. Doxycycline is a tetracycline. Vancomycin is a glycopeptide. Recognizing ciprofloxacin as the fluoroquinolone among agents from other antibiotic classes is the entire task here.

Correct Answer

D — Second-generation fluoroquinolone

Rationale

Ciprofloxacin is a second-generation fluoroquinolone, representing the class-defining advance that transformed fluoroquinolones into broad-spectrum agents. Second-generation agents broadened gram-negative coverage to include reliable antipseudomonal activity and added meaningful activity against atypical intracellular pathogens. Nalidixic acid is the first-generation agent. Levofloxacin is third-generation. Moxifloxacin and gemifloxacin are fourth-generation.

Correct Answer

A — Third-generation fluoroquinolone

Rationale

Levofloxacin is a third-generation fluoroquinolone, also called a respiratory fluoroquinolone because it reliably covers Streptococcus pneumoniae including penicillin-resistant strains — a gap in second-generation coverage. Third-generation agents retain broad gram-negative activity while extending reliable pneumococcal coverage. Nalidixic acid is first-generation. Ciprofloxacin and ofloxacin are second-generation. Moxifloxacin and gemifloxacin are fourth-generation.

Correct Answer

C — Fourth-generation fluoroquinolone

Rationale

Moxifloxacin is a fourth-generation fluoroquinolone. The generation label places it in the most recent fluoroquinolone class, which added clinically relevant anaerobic coverage. Nalidixic acid is first-generation. Ciprofloxacin is second-generation. Levofloxacin is third-generation. Knowing the generation label for moxifloxacin is the task here.

Correct Answer

B — First-generation fluoroquinolone

Rationale

Nalidixic acid is the first-generation fluoroquinolone — the original compound from which the class was developed, with narrow gram-negative spectrum limited to urinary tract pathogens and no systemic use. Ciprofloxacin is second-generation. Levofloxacin is third-generation. Moxifloxacin is fourth-generation. Knowing nalidixic acid's generation label is the task here.

Correct Answer

A — Ciprofloxacin

Rationale

Ciprofloxacin is the fluoroquinolone classified as having the most reliable antipseudomonal activity within the class. Moxifloxacin and gemifloxacin are fourth-generation agents that lack reliable antipseudomonal activity. Nalidixic acid is first-generation with narrow spectrum limited to gram-negative urinary tract pathogens and no antipseudomonal activity. Knowing which fluoroquinolone is classified as the antipseudomonal agent within the class is the task here.

Correct Answer

C — They inhibit deoxyribonucleic acid gyrase and topoisomerase four, generating lethal deoxyribonucleic acid double-strand breaks

Rationale

Fluoroquinolones inhibit two bacterial type two topoisomerases — deoxyribonucleic acid gyrase and topoisomerase four — that are essential for deoxyribonucleic acid replication and cell division. By trapping these enzymes in covalent complexes with cleaved deoxyribonucleic acid strands, fluoroquinolones prevent the enzymes from resealing the breaks they normally introduce transiently, generating persistent double-strand deoxyribonucleic acid damage that is rapidly lethal. This mechanism makes fluoroquinolones bactericidal. The 30S ribosomal subunit is the target of aminoglycosides. Penicillin-binding proteins are the targets of beta-lactams. Membrane disruption is the mechanism of polymyxins and daptomycin.

Correct Answer

A — Levofloxacin achieves approximately 99% oral bioavailability, so oral dosing delivers plasma concentrations nearly equivalent to the same dose given intravenously

Rationale

Levofloxacin's near-complete oral bioavailability of approximately 99% means that almost all of an oral dose is absorbed from the gastrointestinal tract and reaches the systemic circulation. At the same dose, oral and intravenous levofloxacin produce nearly equivalent plasma drug exposures — making oral-to-intravenous interchange on a one-to-one basis pharmacokinetically sound. This property makes unnecessary the routine use of intravenous levofloxacin in patients with a functioning gastrointestinal tract who can swallow, since oral dosing is as effective while avoiding the cost and risks of intravenous access. Moxifloxacin has approximately 89% oral bioavailability, also supporting interchange. Levofloxacin does not undergo first-pass activation, is not degraded intravenously, and has a half-life long enough to support once-daily oral dosing.

Correct Answer

D — Aluminum ions chelate ciprofloxacin in the gastrointestinal lumen, forming an insoluble complex that cannot be absorbed and reducing bioavailability by up to 90%

Rationale

Polyvalent cations including aluminum, magnesium, calcium, iron, and zinc bind to fluoroquinolones in the gastrointestinal lumen, forming insoluble chelate complexes that cannot be absorbed across the intestinal epithelium. Ciprofloxacin is the most severely affected fluoroquinolone, with bioavailability reductions of 50 to 90% when co-administered with cation-containing products. This pharmacokinetic interaction can render oral therapy completely ineffective despite in vitro susceptibility of the pathogen. The interaction does not involve cytochrome P450, gastric pH, or intestinal drug transporters.

Correct Answer

B — Fluoroquinolones impair collagen synthesis and promote collagen degradation in tendon tissue; risk is highest in patients over age 60, receiving concurrent systemic corticosteroids, or who are renal transplant recipients

Rationale

Fluoroquinolones impair the synthesis of new collagen by tendon fibroblasts and simultaneously stimulate collagen-degrading enzymes, weakening the structural integrity of tendon tissue. The Achilles tendon is disproportionately affected because of its relatively poor blood supply and the high mechanical load it sustains. Tendinopathy can appear within 48 hours of starting therapy, and rupture can occur up to months after a course is completed. Three independent risk factors substantially increase the hazard: age over 60 (declining collagen quality), concurrent systemic corticosteroids (additional collagen-impairing effect), and renal transplant status (combination of immunosuppression, corticosteroid use, and altered drug pharmacokinetics). Patients should be counseled to stop the drug immediately and avoid weight-bearing if tendon pain develops.

Correct Answer

A — Fluoroquinolones have a neuromuscular blocking effect that can precipitate life-threatening respiratory failure in patients whose neuromuscular transmission is already severely compromised

Rationale

Fluoroquinolones interfere with neuromuscular transmission. In patients without myasthenia gravis, this effect is subclinical. In patients with myasthenia gravis, whose neuromuscular transmission is already severely impaired by autoimmune destruction of acetylcholine receptors, even modest additional blockade can tip the balance toward respiratory muscle failure. This makes fluoroquinolones absolutely contraindicated in myasthenia gravis. Fluoroquinolones do not induce acetylcholine receptor autoantibodies, do not inhibit acetylcholinesterase, and do not produce neuromuscular junction-specific toxic metabolites.

Correct Answer

C — Moxifloxacin carries the highest QT prolongation risk among fluoroquinolones and is contraindicated in patients with known QT prolongation, uncorrected hypokalemia, or concurrent use of other QT-prolonging agents

Rationale

All fluoroquinolones prolong the corrected QT interval by direct cardiac effects, but the risk is not equivalent across agents. The rank order from highest to lowest QT prolongation risk is moxifloxacin, then levofloxacin, then ciprofloxacin. Moxifloxacin carries the greatest risk within the class and is contraindicated in patients with known baseline QT prolongation, uncorrected hypokalemia (which independently prolongs QT), or concurrent use of other QT-prolonging drugs such as antipsychotics, antiarrhythmics, or certain antiemetics — any of which creates additive risk for torsades de pointes. Ciprofloxacin has the lowest QT risk among the commonly used fluoroquinolones and is not contraindicated with calcium channel blockers on this basis. The contraindication is not applied uniformly to all cardiac arrhythmias.

Correct Answer

D — Ciprofloxacin inhibits cytochrome P450 1A2, the enzyme responsible for theophylline metabolism, causing theophylline to accumulate to toxic concentrations

Rationale

Theophylline is predominantly metabolized by cytochrome P450 1A2. Ciprofloxacin is a potent inhibitor of this enzyme. When the two are co-administered, theophylline metabolism is substantially reduced and plasma theophylline concentrations rise. Because theophylline has a narrow therapeutic index, even modest concentration increases can cause toxicity — manifesting as nausea, vomiting, tachycardia, tremor, and seizures. Theophylline dose reduction and concentration monitoring are required when ciprofloxacin must be used. Levofloxacin and moxifloxacin have minimal cytochrome P450 1A2 inhibitory activity and are safer alternatives in patients on theophylline.

Correct Answer

B — A first mutation in the primary target gene raises the minimum inhibitory concentration modestly; a second mutation in the same or secondary target confers high-level resistance

Rationale

Fluoroquinolone resistance most commonly develops through an accumulation of chromosomal mutations in the genes encoding deoxyribonucleic acid gyrase and topoisomerase four. A single mutation in the primary target gene — gyrase in gram-negative organisms, topoisomerase four in gram-positive organisms — produces a structural change that reduces fluoroquinolone binding affinity and raises the minimum inhibitory concentration to the intermediate range. Alone, this single mutation may not cause outright clinical treatment failure if adequate drug exposure is achieved. However, a second mutation in the same target or the secondary target enzyme produces high-level resistance that is clinically significant. This stepwise pattern explains why agents with balanced activity against both targets, such as moxifloxacin, suppress resistance emergence better — both enzymes must mutate simultaneously for survival. Plasmid-mediated resistance and efflux pumps exist and contribute additional layers of resistance through distinct molecular pathways.

Correct Answer

D — Inhibition of topoisomerase four as the primary target in gram-positive bacteria, trapping the enzyme in a complex with broken deoxyribonucleic acid strands and causing lethal chromosome damage

Rationale

Fluoroquinolones inhibit both deoxyribonucleic acid gyrase and topoisomerase four, but the primary target differs by organism type. In gram-positive bacteria including Streptococcus pneumoniae, topoisomerase four is the primary target. Fluoroquinolones trap topoisomerase four in a covalent complex with cleaved deoxyribonucleic acid strands, preventing the enzyme from resealing the break and generating persistent chromosome damage that is rapidly bactericidal. In gram-negative bacteria, deoxyribonucleic acid gyrase is the primary target. This target primacy is clinically relevant: a mutation in the primary target gene reduces susceptibility and begins the stepwise resistance pathway. The aminoglycoside mechanism involves the 30S ribosomal subunit; the beta-lactam mechanism involves penicillin-binding proteins — both are separate drug class targets distinct from fluoroquinolones.

Correct Answer

B — Aluminum ions chelated ciprofloxacin in the gastrointestinal lumen, forming an insoluble complex that prevented absorption and resulted in subtherapeutic systemic drug concentrations

Rationale

This case illustrates the polyvalent cation chelation interaction — one of the most clinically consequential fluoroquinolone drug interactions. Aluminum ions in the gastrointestinal lumen bind to the carboxyl and oxo groups of the ciprofloxacin molecule, forming an insoluble chelate complex that cannot be absorbed across the intestinal epithelium. Ciprofloxacin taken with or around the time of an aluminum antacid can have its bioavailability reduced by up to 90%, resulting in plasma concentrations far below the minimum inhibitory concentration for the pathogen despite in vitro susceptibility. The pathogen appears sensitive on susceptibility testing because it was tested against adequate drug concentrations in the laboratory — but in the patient, the drug never reached those concentrations. Patients must be counseled to take ciprofloxacin at least two hours before or four to six hours after any polyvalent cation-containing product.

Correct Answer

A — Ciprofloxacin impairs collagen synthesis and promotes collagen degradation in tendon tissue; this patient has two of the highest-risk factors — age over 60 and concurrent corticosteroid use

Rationale

Fluoroquinolone tendinopathy results from direct effects on tendon collagen: impaired synthesis of new collagen by tendon fibroblasts combined with stimulated collagen-degrading enzyme activity weakens the structural integrity of the tendon. The Achilles tendon is most susceptible because of its poor blood supply and high mechanical load. This patient carries two of the three highest independent risk factors: age over 60 and concurrent systemic corticosteroids, which themselves impair collagen synthesis and add to tendon vulnerability. The onset within 48 hours is characteristic and consistent with the known timing. Ciprofloxacin must be stopped immediately and the patient should avoid weight-bearing on the affected leg. Rupture can occur during or months after a course, so complete resolution of symptoms before returning to activity is required.

Correct Answer

C — Moxifloxacin lacks reliable antipseudomonal activity; the fourth-generation gain of anaerobic coverage comes with loss of the Pseudomonas coverage present in second and third-generation fluoroquinolones

Rationale

Moxifloxacin's fourth-generation spectrum represents a trade-off: the addition of clinically relevant anaerobic coverage comes at the cost of losing reliable antipseudomonal activity. This spectrum gap is not a pharmacokinetic problem — moxifloxacin achieves excellent lung tissue concentrations — but a pharmacodynamic one: the drug simply lacks sufficient intrinsic activity against Pseudomonas aeruginosa at clinically achievable concentrations. For Pseudomonas aeruginosa pneumonia, ciprofloxacin or levofloxacin at 750 mg are the appropriate fluoroquinolones. Moxifloxacin is appropriate for aspiration pneumonia and community-acquired pneumonia where anaerobic and atypical coverage are needed, but must never be relied upon for Pseudomonas coverage. Pseudomonas aeruginosa does not inactivate moxifloxacin enzymatically, and moxifloxacin is bactericidal — the problem is spectrum, not mechanism.